Clinical Differences That Matter for Your Decision
Wegovy or Mounjaro Better for UK Availability and Stock Security
The question of whether Wegovy or Mounjaro is better often centres on reliable access, given the supply challenges both treatments have faced globally. At EverydayMeds, we maintain consistent stock levels of both medications through our established relationships with Novo Nordisk and Eli Lilly. All five Wegovy doses (0.25mg through 2.4mg) are currently in stock and ready for next-day delivery, whilst our Mounjaro inventory covers the complete dose range from 2.5mg to 15mg maintenance levels.
When patients ask whether Wegovy or Mounjaro is better from a supply perspective, the answer is that both are reliably available through our GPhC-registered pharmacy (#9012878). We process orders within 3 working days for standard clinical assessments, or 24 hours for our express service. This eliminates the anxiety of treatment interruptions that have affected other suppliers, ensuring your weight management journey continues uninterrupted regardless of which medication your prescriber recommends.
Wegovy or Mounjaro Better Value: UK Pricing Analysis
Determining whether Wegovy or Mounjaro offers better value requires understanding the complete pricing structure for each treatment. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99 (with code FIRST40 for new customers), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing the first 8 weeks of treatment in a single order.
When evaluating whether Wegovy or Mounjaro represents better value, consider the dosing frequency and escalation patterns. Both require weekly injections, but their dose progression schedules differ significantly. Wegovy follows a structured 16-week escalation to maintenance, whilst Mounjaro typically reaches therapeutic levels more quickly. Returning customers can use code DOSE25 at checkout, and our 3-pen bundles like the Ultimate Stability Trio (three 2.4mg pens) provide £649.99 worth of maintenance supply for established patients.
Clinical Evidence: Wegovy or Mounjaro Better Efficacy
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021), compared to 2.4% with placebo. The STEP 2 trial showed around clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 demonstrated roughly clinically studied weight loss when combined with intensive behavioural therapy.
Mounjaro's SURMOUNT trials showed different results due to varying trial designs and patient populations, making direct comparisons inappropriate. When patients ask whether Wegovy or Mounjaro demonstrates better clinical outcomes, the answer depends on individual factors including diabetes status, starting BMI, and concurrent medications. Both treatments are prescription-only medicines that must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone called glucagon-like peptide-1, which your intestines release after eating. This mechanism targets appetite centres in the brain, specifically the hypothalamus, to reduce hunger signals and promote feelings of fullness after smaller meals. The medication may also slow gastric emptying, meaning food stays in your stomach longer, contributing to sustained satiety between meals. Unlike dual-pathway treatments, Wegovy works exclusively through GLP-1 receptors, providing a focused approach to appetite regulation. This targeted mechanism has been extensively studied in the STEP trial programme, establishing semaglutide as a proven option for weight management when prescribed appropriately.
Streamlined Ordering Process for Both Medications
Whether you're considering Wegovy or Mounjaro, our ordering process remains consistent and straightforward across both treatments. The journey begins with a 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any contraindications. Following submission, our prescribers review your assessment within 3 working days (or 24 hours with express service), ensuring appropriate prescribing decisions based on MHRA guidelines and NICE recommendations. Once approved, we dispatch your medication via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. Our pharmacy team coordinates the entire process, from clinical review through to doorstep delivery, ensuring you receive genuine medication from our GPhC-registered facility (#9012878).
Storage and Practical Considerations
When evaluating whether Wegovy or Mounjaro better suits your lifestyle, storage requirements often influence the decision significantly. Wegovy offers a notable advantage with 6 weeks of room temperature stability (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This makes Wegovy more suitable for extended travel, business trips, or situations where refrigeration access is uncertain. Both medications require initial storage at 2-8°C and use similar injection pen technology, though Wegovy's FlexTouch pen system is pre-attached to the needle. The dose escalation schedule for Wegovy spans 16 weeks from 0.25mg starter to 2.4mg maintenance, allowing gradual tolerance development. Each pen delivers exactly 4 doses, making weekly administration straightforward with clear dosing instructions provided.
Wegovy or Mounjaro Better for Different Patient Profiles
The decision between Wegovy or Mounjaro often depends on individual medical circumstances rather than universal superiority. Patients with type 2 diabetes may find Mounjaro's dual GIP/GLP-1 mechanism offers additional glycaemic benefits, whilst those prioritising travel flexibility might prefer Wegovy's extended room temperature stability. Some patients respond better to single-pathway GLP-1 targeting, whilst others benefit from the broader metabolic effects of dual incretin activation.
Your prescriber will consider factors including your BMI classification, existing health conditions, medication history, and lifestyle requirements when determining whether Wegovy or Mounjaro represents the better choice. Both treatments require BMI ≥30 or BMI ≥27 with weight-related comorbidities for prescribing eligibility. The decision isn't about which medication is universally superior, but rather which aligns better with your specific medical profile and treatment objectives.
Order Today: Both Medications Available Now
Rather than wondering whether Wegovy or Mounjaro is better in theory, you can access either treatment through EverydayMeds today without delays or stock concerns. Our current inventory includes all Wegovy doses from 0.25mg starter through 2.4mg maintenance, plus comprehensive Mounjaro supplies across the complete dose range. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 for their discount. Both medications ship next-day following prescriber approval, arriving in temperature-controlled packaging to ensure product quality. Our clinical team remains available for guidance throughout your weight management journey, working alongside your prescriber to ensure optimal treatment outcomes. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment, knowing that both leading weight management treatments are readily available when you need them.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
